Endocrine Abstracts

Background: Pregnancy does not cause differentiated thyroid cancer (DTC) recurrence in patients without structural or biochemical evidence of disease at the time of conception. However, data regarding pregnancy’s impact in patients with persistent DTC before conception are still controversial.Aim: The aim of the study was to determine whether pregnancy could significantly influence the outcome in DTC patients in persistence before pregnancy, but wit...

The management of loco-regional metastases in patients with differentiated thyroid carcinoma is still debated. Current American Thyroid Association guidelines state that in this context the main goal is to differentiate between low-volume metastatic disease that will progress and that remaining stable over time.Aim of our study was to evaluate the behavior of suspicious or cytologically confirmed lymph node metastases, detected after initial treatment (i...

Radioiodine refractory differentiated thyroid cancer can be effectively treated with multi-tyrosine-kinase inhibitors (mTKI). Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but little is known about its pathophysiology and clinical relevance. We report the case of a 78 years old woman treated for a multifocal papillary thyroid cancer, infiltrating perithyroi...

Abstract: An individualized risk-based approach to the treatment of thyroid cancer is being extensively discussed in the recent literature, but controversies remain about the ideal surgical approach. In particular, if some data showed that properly selected thyroid cancer patients can be treated with lobectomy (LT) with excellent clinical outcomes, other results demonstrated an increased incidence of persistent recurrent disease in patients submitted to LT with respect to thos...

Background: Fatigue is one of the most frequently reported adverse events in patients treated with multikinase inhibitors (MKIs). It is present in about 59% and 24% of patients treated with lenvatinib and vandetanib, respectively, associates with a decreased quality of life and often leads to treatment discontinuation. In 2018, for the first time, a correlation between fatigue and primary adrenal insufficiency (PAI) was demonstrated in 12 patients treated with lenvatinib and v...

Objectives: Lenvatinib treatment is responsible for several adverse events (AEs). Hypocalcemia has been described in the registration study in 7% of patients, being of grade ≥3 in 2.7% of cases. No real-life studies are available, and the actual impact of this AE during Lenvatinib treatment is still unknown. Aim of our study is to evaluate the frequency of hypocalcemia in our series of patients treated with Lenvatinib and the possible predictors of this side effect.<...

In the last decades, multi-tyrosine-kinase inhibitors (mTKI) have emerged as an effective treatment for radioiodine refractory differentiated thyroid cancer. Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but up to date little is known about its pathophysiology and relevance. We report the case of a 78 years old woman operated on for a papillary thyroid canc...

TERT promoter mutations (chr5: 1 295 228C>T e chr5: 1 295 250C>T) were recently described in thyroid tumors, with a prevalence ranging 8–25% in papillary thyroid cancer (PTC). We and others reported that these mutations strongly associate with a poor outcome in differentiated thyroid cancers. Aim of the present study was to further investigate the prognostic role of both TERT promoter (TERTMUT) and BRAF<...

Thyroid cancer is highly prevalent in women aged 15–44 years, suggesting that in females the fertile age could be regarded as a risk factor. Consistently, in the last decades epidemiological and experimental findings indicated a possible role of oestrogens in the development and progression of differentiated thyroid tumours. We studied the expression of oestrogen receptor α (ER α) and Progesteron receptor (PR) in 182 female and male patients with papillary thyro...

Recent advances in the molecular classification of papillary thyroid cancer (PTC) have improved the diagnostic work-up and the care of patients with thyroid nodules and cancer, highlighting the need to routinely add information on the genetic pattern to the classification of cancer. The genomic background of a large series of 208 PTCs followed at a single Center was analysed by a custom MA genotyping platform (PTC-MA), which allows the simultaneous detection of 19 genetic alte...